Company: DHR
Filing Date: 2025-07-22
Form Type: 10-Q
Source: 0000313616-25-000153
Chunk: 111

Company: DANAHER CORP /DE/
Filing Date: 2025-07-22
Form: 10-Q
Item: Item 8
Chunk 111
---
, where increased demand in the microelectronic and aerospace end-markets more than offset decreased demand in the energy-related end-market.  

Operating Profit (Loss) Performance

Operating profit margins decreased 2,660 basis points during the three-month period ended June 27, 2025 as compared to the comparable period of 2024.  The following factors unfavorably impacted year-over-year operating profit margin:

•Second quarter 2025 impairment charge related to a trade name.  Refer to Note 8 to the accompanying Consolidated Condensed Financial Statements for additional information - 2,430 basis points

30

•Lower second quarter 2025 core sales, the impact of changes in leverage in the segment’s operational and administrative cost structure and the impact of product mix - 155 basis points

•The incremental dilutive effect in 2025 of acquired businesses - 75 basis points

Operating profit margins decreased 1,440 basis points during the six-month period ended June 27, 2025 as compared to the comparable period of 2024.  

Year-to-date 2025 vs. year-to-date 2024 operating profit margin comparisons were unfavorably impacted by:

•First half of 2025 impairment charge related to a trade name - 1,250 basis points

•Lower first half of 2025 core sales, the impact of product mix, changes in leverage in the segment’s operational and administrative cost structure and the impact of currency exchange rates - 200 basis points

•The incremental dilutive effect in 2025 of acquired businesses - 60 basis points

Year-to-date 2025 vs. year-to-date 2024 operating profit margin comparisons were favorably impacted by:

•First half of 2024 acquisition-related fair value adjustment to inventory - 70 basis points

Depreciation and amortization of intangible assets increased as a percentage of sales during both the three and six-month periods ended June 27, 2025, primarily as a result of the decrease in sales and the impact of acquisitions.  

DIAGNOSTICS

The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.

Diagnostics Selected Financial Data

 Three-Month Period EndedSix-Month Period Ended($ in millions)June 27, 2025June 28, 2024June 27, 2025June 28, 2024Sales$2,